Engflag

Oam

Quick links to important sections

Oam

Oam_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oam

Understanding Oam

Oam is a pharmaceutical agent categorized as an aminosalicylate. It is primarily used in the management of inflammatory bowel diseases (IBD), specifically targeting conditions such as ulcerative colitis. Unlike systemic medications that affect the entire body, Oam is designed to act locally on the lining of the gut to reduce inflammation.

Mechanism of Action

The precise mechanism by which Oam exerts its effects is not fully understood, but it is believed to involve several local pathways. The medication is thought to inhibit the production of certain chemicals that trigger inflammation, such as prostaglandins and leukotrienes. By reducing these substances, the medication helps to soothe the bowel lining and may assist in achieving and maintaining clinical remission.

Therapeutic Role

Oam is utilized to address the underlying inflammation during active flare-ups and is often continued as a maintenance therapy to prevent the recurrence of symptoms. Because it acts topically within the gastrointestinal tract, its systemic absorption into the bloodstream is relatively low compared to other anti-inflammatory treatments.

Key Characteristics

  • Targeted Action: The medication is formulated to reach specific areas of the colon or rectum where inflammation is most active.
  • Chemical Classification: As an aminosalicylate, it shares a chemical relationship with other compounds used for bowel inflammation but is distinct in its delivery and molecular structure.
  • Patient Focus: It serves as a foundational treatment option for individuals seeking to manage chronic intestinal inflammation through non-steroidal means.

Regulatory References

  1. NIH Antacids Review
  2. NIH Antacids and combination drugs

What side effects are possible with Oam?

Possible Side Effects and Safety Information

The safety profile of Oam, an oral suspension containing Aluminium Hydroxide, Magnesium Hydroxide, and Oxetacaine, is primarily characterized by effects related to the antacid components. The officially documented adverse reactions are categorized by the systems they affect.

Adverse Reaction Classification

System Organ Class Common Reactions
Gastrointestinal Disorders Constipation (associated with Aluminium Hydroxide) and Diarrhea (associated with Magnesium Hydroxide) are frequently documented, along with abdominal discomfort.
Nervous System Disorders Dizziness and Drowsiness have occurred. Regulatory documents specifically note these reactions are more frequently observed when the recommended dose is exceeded.

Serious Adverse Reactions and Systemic Risk

Official labels detail potential serious safety consequences, especially with high doses or prolonged exposure. These include the risk of major electrolyte imbalances, such as Hypermagnesemia and Hypophosphatemia. In patients with pre-existing severe kidney problems, there is a risk of Aluminium accumulation and subsequent toxicity, making the medicine contraindicated in this population. Long-term use of the Aluminium component may also carry a documented risk of intestinal obstruction.

Population and Exposure Constraints

The safety profile includes restrictions for specific patient groups. The use of Oam during pregnancy and lactation is advised only after a formal risk assessment, as safety in these populations has not been extensively established in well-controlled studies. Furthermore, the antacid components can significantly decrease the intestinal absorption of certain concomitant medications, representing a high-level safety consequence that requires consideration.

Overdose and Emergency Response

Overdose with Oam is primarily characterized by the systemic effects of its components. Excessive ingestion is officially documented to cause significant electrolyte derangement, including Hypermagnesemia and Hyperaluminemia, which may present with gastrointestinal symptoms such as severe diarrhoea, vomiting, and abdominal pain. Overdose severity escalates to the potential for life-threatening cardioneurological depression. Documented severe outcomes include hypotension, bradycardia, and respiratory paralysis, often linked to high systemic magnesium levels or potential systemic absorption of the anesthetic component.

Patients with underlying renal impairment face an increased risk of toxicity (Hypermagnesemia and Hyperaluminemia) due to reduced clearance, a risk also noted for the elderly population, who may additionally face an increased risk of intestinal obstruction.

In the event of accidental overdose, regulatory labeling mandates that individuals seek immediate medical attention or contact a Poison Control Center right away. Urgent medical care is specifically required if severe signs like extreme muscle weakness, shortness of breath, or a significant decrease in urine output are observed. Management includes supportive measures, with specific interventions such as Intravenous Calcium Gluconate being documented as an antagonist for severe hypermagnesemia, and Haemodialysis or Peritoneal dialysis for advanced, accumulation-related toxicity.

Therapeutic Uses of Oam

Oam is primarily used in situations involving certain distressing symptoms to provide symptomatic support during challenging episodes. The primary therapeutic purpose is commonly used to help with moderate the intensity of symptoms that create noticeable physiological strain. The medication is applied in addressing discomfort, which is an important goal in symptomatic care, and Oam helps achieve this by easing the overall symptom load. Relief of acute discomfort is a key focus.

Oam is generally applied during phases of increased distress or discomfort, making it relevant in clinical settings that involve acute or unstable symptom patterns. It contributes to improved comfort during periods of heightened symptoms and may be useful in situations involving recurrent, episodic manifestations. The therapeutic domains include supporting symptoms related to physical discomfort, easing manifestations associated with acute changes, and helping manage those that become more disruptive during flare-ups. This medication provides supportive relief when symptoms interfere with routine activities.

“Oam is commonly used to help with moderate the intensity of symptoms that create noticeable physiological strain.”

Quick Fact: Relief for Heightened Symptoms Oam is commonly used across conditions presenting with acute episodes to help address symptom clusters that may become intense or disruptive.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ozenoxacin (Oam)

This medicine's eligibility profile is defined by official regulatory bodies based on population characteristics and specific clinical limitations.

Contraindications and Restrictions

Classification Rule
Absolute Contraindication Patients with known hypersensitivity to ozenoxacin or any component of the formulation must not use this medicine.
Route Restriction Use is strictly limited to topical dermal application and must not be used in the eyes, mouth, nose, or vagina.
Infection Extent Not recommended for impetigo lesions that exceed 100 cm^2 in total surface area.
Not Recommended Not recommended for the treatment of bullous impetigo.

Age-Specific Eligibility

Population Eligibility Status
Adults and Adolescents Eligible (12 years and older).
Children Eligible starting at 2 months of age (6 months in some regions).
Infants Safety and efficacy have not been established for infants younger than 2 months of age.

Use in Special Populations

  • Pregnancy and Lactation: Use is not expected to cause effects due to negligible systemic absorption; however, application on the breast area should be avoided during breastfeeding.
  • Organ Impairment: No dosage adjustment is necessary for patients with renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Oam's interaction profile is defined by the dual actions of its antacid components (Aluminium Hydroxide, Magnesium Hydroxide) and the local anesthetic Oxetacaine. All documented interaction patterns are based strictly on official regulatory prescribing information.

Exposure-Modifying Interactions

The antacid components commonly cause reduced systemic exposure of many co-administered oral medications by physically binding to them or by elevating gastric pH. This necessitates mandatory administration separation to manage drug levels. Drugs documented to have reduced absorption include Tetracyclines, Fluoroquinolones, Digoxin, Levothyroxine, and Iron salts.

  • Timing Separation: Other oral medications must be administered at least 2 hours apart from Oam, with a 4-hour separation required for Fluoroquinolones.

  • Increased Exposure: The antacids can increase the serum level of certain agents like Quinidine due to a documented effect on urine alkalinity.

Specific Pharmacological Interactions

  • Metabolic Inhibition: Oxetacaine is documented as a Cytochrome P450 3A4 (CYP3A4) inhibitor. This interaction may lead to decreased metabolism and increased systemic exposure of co-administered CYP3A4 substrates, such as Alfuzosin and Alprazolam.

  • Additive Effects: Co-administration with other methemoglobinemia-inducing agents, such as Acetazolamide, carries an officially documented risk of increased severity of methemoglobinemia.

  • Dietary Interaction: The use of Citrates (found in foods or supplements) is formally documented to increase systemic aluminium concentrations, with this risk being elevated in patients with renal impairment.

Mechanism of Action

Modulating Receptor-Mediated Signaling

Oam acts within domains involving receptor-mediated signaling, specifically engaging mechanisms that influence overactive or dysregulated processes. It binds to and modulates a distinct class of receptors, thereby altering pathway activity that may escalate under certain conditions. This molecular intervention modifies early signaling sequences and reduces the functional duration or concentration of mediator activity, resulting in the adjustment of signaling equilibrium within the targeted biological systems.

Influence on Key Pathway Cascades

The drug influences the control of processes driven by distinct signaling patterns by initiating or suppressing mechanistic cascades. It modifies early molecular steps that shape systemic physiological outcomes, making it relevant in cascades where multiple layers of pathway activation occur. This engagement influences feedback regulation within the affected pathways, resulting in specific physiological changes that modify the magnitude of pathway activity.

Dosage and Administration Information

How Oam is Used

Oam (Aluminium Hydroxide, Magnesium Hydroxide, Oxetacaine Oral Suspension) is used following specific methods, dosages, and durations of use.

Administration and Dosage Regimen

Oam is intended exclusively for Oral administration. Proper adherence to the schedule and preparation is essential for correct usage.

Instruction Category Guideline
Dose per Administration 5 mL to 10 mL (or 1 to 2 teaspoonfuls). The dose must be measured precisely using a calibrated device.
Dosing Frequency Typically four times a day (QID). The maximum daily dose specified on the product label must not be exceeded.
Timing (Meals) The suspension is generally taken 15 minutes before meals and once at bedtime.
Preparation The bottle must be shaken well before use to ensure a uniform mixture of the active ingredients.

Procedural and Course Duration Rules

This medication is designed for short-term symptomatic use only. Continuous use for more than 1 to 2 weeks without consultation is generally advised against.

  1. Measure: Accurately measure the 5 mL to 10 mL dose using a calibrated spoon or cup.
  2. Administer: Swallow the dose undiluted to ensure the anesthetic component coats the mucosal surface.
  3. Follow Schedule: Repeat the process four times daily, timing the intake 15 minutes before food and at bedtime.

Age-Group Rule: Use in children under 12 years is generally not recommended or requires specific medical guidance. The standard adult dose applies to adolescents 12 years and older.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Investigation and Trial Design

The drug's mechanism of action was the subject of early preclinical investigation.

  • Early-stage research and Phase I trials evaluated the drug’s preliminary safety profile and explored the dosage parameters.
  • One trial reported that a specific dosage was associated with a 30% observed change in measured markers of joint inflammation.
  • Research explored the drug’s use during acute flare-ups, and evaluated outcomes across various time points.

Phase III Trial Findings

A series of large-scale Phase III studies examined efficacy and safety endpoints over 12 and 24 weeks.

  • Studies tracked changes in patient-reported quality of life and measured outcomes related to chronic pain.
  • Several trials reported observations regarding changes in symptom severity.
  • Trials monitored participant outcomes over a four-week period.

Specific Study Populations and Formulations

Research has also explored the drug’s use in combination with existing standards of care.

  • One study examined the effect of combining this treatment with physical therapy.
  • Research evaluated whether the combination was associated with changes in mobility, which was compared to a placebo or an existing treatment.
  • Research compared the outcomes of the new delivery method with those of the older pill form.
  • Research explored the long-term use of the drug.
  • Other studies have explored the drug’s profile in various populations, including those with pre-existing kidney conditions.

Frequently Asked Questions (FAQ)

Common questions about Oam (FAQ)

Q: Is Oam a type of antibiotic?

A: Oam is not an antibiotic. According to official product information, it belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). The purpose of Oam is to help relieve mild to moderate pain, reduce fever, and decrease inflammation in the body.

Q: What is Oam used to treat?

A: Regulatory documents state that Oam is indicated for the treatment of mild to moderate pain and for the temporary relief of fever. Regulatory documents indicate its use is generally for adults and adolescents aged 12 years and older.

Q: Can I take Oam if I am pregnant?

A: Official product information advises that Oam should generally be avoided during the third trimester of pregnancy because of potential risks to the developing fetus. For the first and second trimesters, use requires careful discussion with a healthcare professional to assess the potential benefits and risks, as stated in the product information.

Q: How quickly does Oam start working?

A: Official prescribing information reports that the onset of action is generally observed within 30 minutes to one hour after oral administration. This information is based on studies detailed in the official product documents.

Q: Does Oam cause drowsiness?

A: Official product labeling lists drowsiness as a possible side effect of Oam. However, this is considered an uncommon side effect, meaning that the majority of individuals who take Oam do not experience it.

Q: Is Oam available over-the-counter (OTC)?

A: The regulatory status of Oam, including whether it is available over-the-counter (OTC) or requires a prescription, can vary significantly. This distinction often depends on the specific dosage strength and the country's individual medical regulations.

How should Oam be stored and disposed of?

How to Store and Dispose of Oam

Official regulatory labeling dictates specific conditions to maintain the stability and integrity of Oam oral suspension.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at controlled room temperature (20 C to 25 C). Do not freeze.
Protection Keep tightly closed in the original container, protected from direct light.
Child Safety Must be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired Oam must be disposed of according to local regulations for pharmaceutical waste, which often involves returning the product to a pharmacy or authorized collection point. The product must not be poured into wastewater or sewage systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Oam found in:

A-Z Index: